A
Alcista
Alcista · 25%INCY
$76.77
Precio del escenario
$113.250
+1.710 (+1.51%)Al cierre
Loading chart…
- Máximo
- 115.830
- Apertura
- 113.360
- Precio medio ponderado por volumen
- 114.08
- Volumen
- 1.93M
- Capitalización
- 12.09B
- Mínimo
- 113.150
- Importe
- 220.01M
- EV/EBITDA, TTM
- 6.65
Incyte Corporation is a biopharmaceutical company engaged in the discovery, development, and commercialization of therapeutics. It operates in three therapeutic areas: Hematology, Oncology, and Inflammation and Autoimmunity. Its hematology franchise includes four approved products, JAKAFI (ruxolitinib), ICLUSIG (ponatinib), MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) and NIKTIMVO (axatilimab-csfr), as well as multiple clinical development programs. Its oncology franchise includes two approved products, PEMAZYRE (pemigatinib) and ZYNYZ (retifanlimab-dlwr), as well as several clinical development programs. Its Inflammation and Autoimmunity franchise consists of one approved product, OPZELURA (ruxolitinib) cream, with several clinical programs in development. It also includes VGA039, a novel monoclonal antibody in Phase III development for von Willebrand disease (VWD). It manages business activities through the development and commercialization of oncology and dermatology products.
Análisis de IA of Incyte Corp (INCY)
MantenerIncyte Corp is currently priced at $112.79, which is below the average analyst price target of $135.75, indicating potential upside. However, the RSI is at a low 18.75, suggesting the stock is oversold, which could lead to a rebound. The main risk is the recent 5-day change of -2.18%, indicating short-term weakness.
Recomendaciones de analistas (21)
-11.43% Potencial de caída
Comprar
17 Comprar
4 Mantener
0 Vender
Actual: 113.25
Mínimo
73.00
Promedio
100.31
Máximo
125.00
RBC Capital
Sector Perform
$114
2026-10-08
RBC Capital
2026-10-08
Precio objetivo
$114
Sector Perform
Stifel
Comprar
$157
2026-10-05
Stifel
2026-10-05
Precio objetivo
$157
Comprar
JPMorgan
Neutral
$123
2026-09-28
JPMorgan
2026-09-28
Precio objetivo
$123
Neutral
Canaccord
Comprar
$152
2026-08-20
Canaccord
2026-08-20
Precio objetivo
$152
Comprar
Bernstein
Market Perform
$104
2026-08-13
Bernstein
2026-08-13
Precio objetivo
$104
Market Perform
Métricas de valoración
El PER previsto actual de Incyte Corp (INCY) es 14.71, frente a su media de 5 años de 17.96.
Escenarios de precio de Alphio AI para INCY
Los precios por escenario son la última banda de previsión mensual del año en curso. Las probabilidades son pesos fijos del modelo (25 / 50 / 25), no garantías.
Ballenas con INCY en cartera
Cronología de eventos
Noticias
5.009-28PRnewswireMiniMed Appoints New General Counsel
9.009-28stocktwitsFDA Decisions Loom for Bristol Myers and Others
9.009-27NASDAQ.COMFDA Approves Atebrioz for Rare Disease Treatment
9.009-27NASDAQ.COMFDA Approves Olumiant for Pediatric Alopecia Areata Treatment
8.509-25NewsfilterFDA Approves ALK2 Inhibitor Atebrioz for FOP Treatment
Preguntas frecuentes sobre INCY, respondidas por Alphio AI
Incyte Corporation is a biopharmaceutical company engaged in the discovery, development, and commercialization of therapeutics. It operates in three therapeutic areas: Hematology, Oncology, and Inflammation and Autoimmunity. Its hematology franchise includes four approved products, JAKAFI (ruxolitinib), ICLUSIG (ponatinib), MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) and NIKTIMVO (axatilimab-csfr), as well as multiple clinical development programs. Its oncology franchise includes two approved products, PEMAZYRE (pemigatinib) and ZYNYZ (retifanlimab-dlwr), as well as several clinical development programs. Its Inflammation and Autoimmunity franchise consists of one approved product, OPZELURA (ruxolitinib) cream, with several clinical programs in development. It also includes VGA039, a novel monoclonal antibody in Phase III development for von Willebrand disease (VWD). It manages business activities through the development and commercialization of oncology and dermatology products. It operates in the Healthcare sector (SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH industry).
Incyte Corp is currently priced at $112.79, which is below the average analyst price target of $135.75, indicating potential upside. However, the RSI is at a low 18.75, suggesting the stock is oversold, which could lead to a rebound. The main risk is the recent 5-day change of -2.18%, indicating short-term weakness.
21 analysts cover INCY: 17 rate it Buy, 4 Hold and 0 Sell. The average price target is 100.31.
Comunidad
Más ↗
$MIRM $INCY Mirum Pharmaceuticals and Incyte announced that the U.S. FDA has approved Atebrioz tablets to reduce the volume of total new heterotopic ossification in adult and pediatric patients aged 12 years and older with fibrodysplasia ossificans progressiva. The recommended dose of Atebrioz is 100 mg administered orally, once daily.
Mostrar másEsta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.